The association between MMF and risk of progressive renal dysfunction and death in adult liver transplant recipients with HCV

Clinical Transplantation

Volumn 23, Issue 1, 2009, Pages 108-115

  Lake, John ^a,b   Patel, Dharmesh ^c   David, Kristin ^d   Richwine, Jason ^d   Morris, Jonathan ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d ProSanos Corporation   (United States)

Author keywords

Chronic kidney disease; Hepatitis C; Immunosuppression; Liver transplantation; Mycophenolate mofetil

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 63349090890     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00916.x     Document Type: Article

References (27)

1. Kim DY, Lim C, Parasuraman R et al. Renal disease burden following liver transplantation. Transplant Proc 2006: 38: 3663.
2. O'Riordan A, Wong V, Mc Cormick PA, Hegarty JE, Watson AJ. Chronic kidney disease postliver transplantation. Nephrol Dial Transplant 2006: 21: 2630.
3. Guitard J, Ribes D, Kamar N et al. Predictive factors for chronic renal failure one year after orthotopic liver transplantation. Ren Fail 2006: 28: 419.
4. Cohen AJ, Stegall MD, Rosen CB et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002: 8: 916.
5. Morard I, Mentha G, Spahr L et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 2006: 20: 96.
6. Asfandiyar S, Abouljoud M, Kim D et al. Influence of hepatitis C on renal function after liver transplantation. Transplant Proc 2006: 38: 3643.
7. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
8. Futagawaa Y, Terasakia PI, Wakia K, Caia J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: An analysis of the UNOS data. Am J Transplant 2006: 6: 1398.
9. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003: 75: 1341.
10. Beckebaum S, Cicinnati VR, Klein CG et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: Preliminary results of an open prospective study. Transplant Proc 2004: 36: 2671.
11. Frimat L, Cassuto-Viguier E, Charpentier B et al. Impact of cyclosporine reduction with MMF: A randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006: 6: 2725.
12. Jimenez-Perez M, Lozano Rey JM, Marin Garcia D, Olmedo M artinR, de la Cruz Lombardo J, Rodrigo Lopez JM. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation. Transplant Proc 2006: 38: 2480.
13. Lake JR, Chu AH, Steffen BJ et al. Efficacy of triple therapy with mycophenolate mofetil, tacrolimus and corticosteroids compared to tacrolimus and corticosteroids immunosuppression in liver transplantation: An analysis of the US liver transplant experience (abstract). Am J Transplant 2004: 4: 266.
14. Wiesner RH, Steffen BJ, David KM, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients. Am J Transplant 2006: 6: 1609.
15. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005: 11: 750.
16. Go AS, Chertow GM, Dongjie Fan D, Mc Culluch CE, Hsu C. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 2004: 351: 1296.
17. Chiara M, Menegatti E, Di Simone D et al. Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27kip1 expression in anti Thy1 mesangial proliferative nephritis. Clin Exp Immunol 2005: 9: 225.
18. Nankivell BJ, Wavamunno MD, Borrows RJ et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007: 7: 366.
19. Gonzalez Molina M, Seron D, Garcia del Moral R et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004: 77: 215.
20. Turner S, Dhamarajah S, Bosomworth M, Bellamy MC. Leeds Liver Transplant Group. Effect of perioperative steroids on renal function after liver transplantation. Anaesthesia 2006: 61: 253.
21. Baker RC, Armstrong MA, Young IS et al. Methylprednisolone increases urinary nitrate concentrations and reduces subclinical renal injury during infrarenal aortic ischemia reperfusion. Ann Surg 2006: 244: 821.
22. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome -experience in 300 patients. Transplantation 1991: 51: 428.
23. Campbell MS, Kotlyar DS, Brensinger CM et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 2005: 11: 1048.
24. Hong MKh, Angus PW, Jones RM, Vaughan RB, Gow PJ. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant 2005: 19: 193.
25. Velidedeoglu E, Bloom RD, Crawford MD et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation 2004: 77: 553.
26. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003: 9: 741.
27. Lucey MR, Abdelmalek MF, Gagliardi R et al. A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status. Am J Transplant 2005: 5: 1111.